Abstract
The current vaccination strategy is aimed at eliciting neutralizing antibody responses against surface antigens of pathogens. Although antibody-mediated immunity to the surface of antigens reduces the probability of infection and morbidity, an antibody against one virus type or subtype can provide limited or no protection against another. We developed liposome vaccine which is capable of inducing CTL response against internal antigens of influenza viruses and removing virus-infected cells in the host. The CTL-based liposomal vaccine might be applicable for the development of vaccines against influenza and other viruses which frequently changes their surface antigenic molecules.
